DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA604418
Title:
Development of Lead Compounds as Fusion Inhibitors for Dengue Virus
Descriptive Note:
Final rept. 11 Jul 2008-10 Jun 2009
Corporate Author:
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE SANTIAGO
Report Date:
2009-08-01
Pagination or Media Count:
61.0
Abstract:
Identification of antiviral agents is critical to the development of therapeutic treatments directed against dengue virus DENV, for which there is no specific therapy. The structures of the dengue virus class II fusion envelope proteins E suggest several features that could be explored as targets for inhibition. This report describes the activities, methods and approaches used for the design and identification of chemical entities targeting the dengue virus fusion process mediated by the E glycoprotein. The compound were designed to target the essential pH dependent conformational changes that occurs in the envelope protein E protein, by inhibiting the conformational rearrangement that allows the virus-host membrane fusion.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE